Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia

Carsten U Niemann; Mark-David Levin; Julie Dubois; Sabina Kersting; Lisbeth Enggaard; Gerrit J Veldhuis; Rogier Mous; Clemens H M Mellink; Johan A Dobber; Christian B Poulsen; Henrik Frederiksen; Ann Janssens; Ida Schjødt; Ellen C Dompeling; Juha Ranti; Mattias Mattsson; Mar Bellido; Hoa T T Tran; Kazem Nasserinejad; Arnon P Kater

doi:10.1182/blood.2020008608

Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia

Blood. 2021 Feb 25;137(8):1117-1120. doi: 10.1182/blood.2020008608.

Authors

Carsten U Niemann¹, Mark-David Levin², Julie Dubois³, Sabina Kersting⁴, Lisbeth Enggaard⁵, Gerrit J Veldhuis⁶, Rogier Mous⁷, Clemens H M Mellink⁸, Johan A Dobber⁹, Christian B Poulsen¹⁰, Henrik Frederiksen¹¹, Ann Janssens¹², Ida Schjødt¹, Ellen C Dompeling¹³, Juha Ranti¹⁴, Mattias Mattsson¹⁵, Mar Bellido¹⁶, Hoa T T Tran¹⁷, Kazem Nasserinejad¹⁸, Arnon P Kater³

Affiliations

¹ Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
² Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
³ Department of Hematology, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam, The Netherlands.
⁴ Department of Hematology, Haga Ziekenhuis, Den Haag, The Netherlands.
⁵ Department of Hematology, Herlev Hospital, Copenhagen, Denmark.
⁶ Department of Hematology, Antonius Ziekenhuis, Sneek, The Netherlands.
⁷ Department of Hematology, Universitair Medisch Centrum Utrecht, Utrecht, The Netherlands.
⁸ Department of Clinical Genetics and.
⁹ Laboratory of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
¹⁰ Department of Hematology, Roskilde University Hospital, Roskilde, Denmark.
¹¹ Department of Hematology, Odense University Hospital, Odense, Denmark.
¹² Department of Hematology, Universitair Ziekenhuis Leuven, Leuven, Belgium.
¹³ Department of Hematology, Isala Ziekenhuis, Zwolle, The Netherlands.
¹⁴ Department of Hematology, Turku University Central Hospital, Turku, Finland.
¹⁵ Department of Hematology, Uppsala University Hospital, Uppsala, Sweden.
¹⁶ Department of Hematology, UMC Groningen, University of Groningen, Groningen, The Netherlands.
¹⁷ Department of Hematology, Akershus University Hospital, Lørenskog, Norway; and.
¹⁸ HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

PMID: 33027809
DOI: 10.1182/blood.2020008608

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adenine / analogs & derivatives*
Adenine / therapeutic use
Adult
Aged
Aged, 80 and over
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use*
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Male
Middle Aged
Neoplasm Recurrence, Local / drug therapy
Piperidines / therapeutic use*
Protein Kinase Inhibitors / therapeutic use*
Sulfonamides / therapeutic use*
Treatment Outcome

Substances

Antineoplastic Agents
Bridged Bicyclo Compounds, Heterocyclic
Piperidines
Protein Kinase Inhibitors
Sulfonamides
ibrutinib
Adenine
venetoclax